MAGEA4 Antibody

Product Specifications

Background

MAGEA4 is a member of the melanoma-associated antigen family that consists of a number of antigens recognized by cytotoxic T lymphocytes (1) . MAGEA4 may serve as a target for antitumoral vaccination and may play a role in embryonal development and tumor transformation or aspects of tumor progression. It is expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma and have been implicated in some hereditary disorders, such as dyskeratosis congenital (2-4) .

NCBI Gene ID

4103

Swiss Prot

P43358

Accession Number

NP_001011550

Host

Rabbit

Reactivity

Human, Mouse, Rat

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Stem Cell, Cancer

Purification

MAGEA4 antibody is affinity chromatography purified via peptide column.

Positive Control

Cat. No. 1202 - A431 Cell Lysate

Concentration

1 mg/mL

Buffer

MAGEA4 antibody is supplied in PBS containing 0.02% sodium azide.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

MAGEA4 antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year.

Observed Molecular Weight

Multiple independent MAGEA4 antibodies also show a band at ~45 kDa

Fragment

IgG

Specificity

MAGEA4 antibody is human specific. At least four isoforms of MAGEA4 are known to exist.

Symbol

MAGEA4

Positive Control 2

Cat. No. 10-001 - Human Breast Tissue Slide

NCBI Official Name

Melanoma antigen family A, 4

NCBI Organism

Homo sapiens

Background Reference 01

Bhan S, Negi SS, Shao C, et al. BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer. Clin. Cancer Res. 2011; 17:4267-76.

Background Reference 02

Bhan S, Chuang A, Negi SS, et al. MAGEA4 induces growth in normal oral keratinocytes by inhibiting growth arrest and apoptosis. Oncol. Rep. 2012; 28:1498-502.

Background Reference 03

Saito T, Wada H, Yamasaki M, et al. High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine, epub. 2014; S0264-410X (14) 01217-1.

Background Reference 04

Zhang QM, He SJ, Shen N, et al. Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target. Int. J. Clin. Exp. Pathol. 2014; 7:3918-27.